Allarity Therapeutics, Inc. Proceeds from Notes Payable
Allarity Therapeutics, Inc. (ALLR) reported Proceeds from Notes Payable of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-03-30
- Allarity Therapeutics, Inc. proceeds from notes payable for the quarter ending 2024-12-31 was $0.00.
- Allarity Therapeutics, Inc. proceeds from notes payable for the quarter ending 2024-09-30 was $0.00.
- Allarity Therapeutics, Inc. proceeds from notes payable for the quarter ending 2024-06-30 was $0.00.
- Allarity Therapeutics, Inc. proceeds from notes payable for the quarter ending 2024-03-31 was $1.34M.
- Allarity Therapeutics, Inc. proceeds from notes payable for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Allarity Therapeutics, Inc. proceeds from notes payable for fiscal 2024 was $1.34M, a 27.62% increase from fiscal 2023.
- Allarity Therapeutics, Inc. proceeds from notes payable for fiscal 2023 was $1.05M, a 5.00% increase from fiscal 2022.
- Allarity Therapeutics, Inc. proceeds from notes payable for fiscal 2022 was $1.00M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-30 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $0.00 derived: sum of 3 quarters · filed 2026-03-30 | $1.34M 10-K · filed 2026-03-30 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $1.34M 10-Q · filed 2024-11-14 | $1.34M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $1.34M 10-Q · filed 2024-08-05 | $1.34M derived: sum of 3 quarters · filed 2025-03-31 | $1.34M derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $1.34M 10-Q · filed 2024-05-14 | $1.34M derived: sum of 2 quarters · filed 2025-03-31 | $1.34M derived: sum of 3 quarters · filed 2025-03-31 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $1.05M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.05M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $1.05M 10-Q · filed 2024-08-05 | |||
| 2022-12-31 | $1.00M 10-K · filed 2024-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |